Ikena Oncology, Inc.

NasdaqGM IKNA

Ikena Oncology, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -61.56 M

Ikena Oncology, Inc. Operating Cash Flow is USD -61.56 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 18.54% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Ikena Oncology, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -75.58 M, a -8.25% change year over year.
Ikena Oncology, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -69.82 M, a -17.44% change year over year.
Ikena Oncology, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -59.45 M.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NasdaqGM: IKNA

Ikena Oncology, Inc.

CEO	Dr. Mark Manfredi Ph.D.
IPO Date	March 26, 2021
Location	United States
Headquarters	645 Summer Street
Employees	14
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Key trends

Past 5 years